Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma

Esophageal squamous cell carcinoma is a common malignancy in China. Although neoadjuvant chemoradiotherapy followed by esophagectomy remains a standard modality for locally advanced esophageal squamous cell carcinoma, esophagectomy followed by postoperative radiotherapy is also prevalent in China. Several retrospective studies demonstrated that postoperative radiotherapy could improve the prognosis of patients. Nevertheless, there still existed approximately 11.5% and 17.2% of total patients developing local-regional relapse and hematological metastasis. The result of Checkmate 577 has shown t

Trial Details

NCT ID
NCT05937438
Phase
PHASE1 / PHASE2
Sponsor
Anhui Provincial Hospital
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Immune Checkpoint Inhibitors
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083

Key Eligibility Criteria

  • 18-75 years old.
  • After esophagectomy.
  • Confirmation of squamous cell carcinoma by pathological examination.
  • Pathological staging of pIIb-IVa.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →